#United States #New York #medical technology #Nasdaq Listing #Davion Healthcare

Davion Healthcare’s Key Milestone: Automatic SEC Approval

On November 28, 2025, Davion Healthcare Plc, a pioneering medical technology firm, announced a significant achievement in its journey towards becoming a publicly traded company. The firm's Registration Statement on Form F-1 has automatically become effective under Section 8(a) of the Securities Act of 1933, as confirmed by the U.S. Securities and Exchange Commission (SEC). This development marks a critical step for Davion as it seeks to list its shares on the NASDAQ Capital Market.

Effective Filing and Future Steps

Filed on November 7, 2025, the Form F-1 is not just a routine registration; it signifies the entrance of Davion Healthcare into the public market. Beyond this registration, the company has also submitted a Form 8-A to register its ordinary shares according to Section 12(b) of the Securities Exchange Act of 1934. Currently, Davion is finalizing the necessary administrative steps with NASDAQ to ensure a smooth trading admission. An announcement regarding the listing date is anticipated soon, heightening investor expectations.

About Davion Healthcare

Davion Healthcare Plc is focused on advancing healthcare through non-invasive technologies aimed at early-stage identification of medical anomalies, with a strong emphasis on cancer screening. The company's flagship product, BreastCheck™, is an innovative at-home breast health screening solution. Utilizing a thermosensitive patch paired with a companion mobile application, BreastCheck™ empowers users to detect anomalies efficiently without requiring an in-person clinical visit. The commercial launch of this groundbreaking product is slated for the end of H1 2026.

The firm's approach is characterized by a capital-light, licensing-led model which involves designing proprietary monitoring tools while collaborating with third-party entities for manufacturing and distribution. This business strategy allows Davion to maintain operational efficiency while rapidly expanding its product offerings.

Innovative Product Pipeline

In addition to BreastCheck™, Davion is developing a robust product pipeline. Notable advancements include:

• - FootFlow™: A non-invasive tool for monitoring foot temperature, crucial for the early detection of Peripheral Artery Disease (PAD) and diabetes.
• - Testic™: An at-home test for monitoring testicular health.
• - ThermaDerm™: A clinician-facing thermal monitoring pad designed for the detection of skin anomalies.

The overarching mission of Davion Healthcare is to enhance access to early detection tools, thereby alleviating pressure on healthcare systems. By providing affordable and accessible technologies, the company aims to foster informed medical interventions at earlier stages.

Conclusion

As Davion Healthcare Plc prepares for its public offering, the positive response to its SEC registration reflects increasing investor interest in innovative medical technologies aiming to revolutionize healthcare. With its commitment to early-stage detection and user-friendly home testing solutions, Davion is poised to make a substantial impact in the healthcare sector. For more information, visit Davion Healthcare's official website.